{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T18:37:14Z","timestamp":1792521434079,"version":"4.5.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":67,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Shandong Province Traditional Chinese Medicine Science and Technology Project"},{"name":"the Faculty Research Support Fund of Jining Medical University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-16291-w","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T13:36:15Z","timestamp":1780580175000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prognostic value of CA125, HE4, ROMA, and CPH-I in advanced epithelial ovarian cancer"],"prefix":"10.1186","volume":"26","author":[{"given":"Minli","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tengteng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sijin","family":"Man","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuohao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"issue":"3","key":"16291_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"10440","key":"16291_CR2","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1016\/S0140-6736(24)00367-2","volume":"403","author":"Global burden of","year":"2024","unstructured":"Global burden of. 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990\u20132021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403(10440):2100\u201332.","journal-title":"Lancet"},{"issue":"3","key":"16291_CR3","doi-asserted-by":"publisher","first-page":"635","DOI":"10.4143\/crt.2016.282","volume":"49","author":"ES Paik","year":"2017","unstructured":"Paik ES, Sohn I, Baek SY, Shim M, Choi HJ, Kim TJ, Choi CH, Lee JW, Kim BG, Lee YY, et al. Nomograms predicting platinum sensitivity, progression-free survival, and overall survival using pretreatment complete blood cell counts in epithelial ovarian cancer. Cancer Res Treat. 2017;49(3):635\u201342.","journal-title":"Cancer Res Treat"},{"issue":"1","key":"16291_CR4","doi-asserted-by":"publisher","first-page":"349","DOI":"10.21873\/anticanres.15492","volume":"42","author":"J Lee","year":"2022","unstructured":"Lee J, Kim JM, Lee YH, Chong GO, Hong DG. Correlation between clinical outcomes and serum CA-125 levels after standard treatment for epithelial ovarian cancer. Anticancer Res. 2022;42(1):349\u201353.","journal-title":"Anticancer Res"},{"issue":"1","key":"16291_CR5","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ygyno.2021.05.001","volume":"162","author":"DT Tran","year":"2021","unstructured":"Tran DT, Vo VK, Le MT, Chuang L, Nguyen VQH. Copenhagen Index versus ROMA in preoperative ovarian malignancy risk stratification: result from the first Vietnamese prospective cohort study. Gynecol Oncol. 2021;162(1):113\u20139.","journal-title":"Gynecol Oncol"},{"key":"16291_CR6","doi-asserted-by":"crossref","unstructured":"Carreras-Dieguez N, Glickman A, Munmany M, Casanovas G, Agust\u00ed N, D\u00edaz-Feijoo B, Saco A, S\u00e1nchez B, Gaba L, Angeles MA et al. Comparison of HE4, CA125, ROMA and CPH-I for preoperative assessment of adnexal tumors. Diagnostics (Basel). 2022;12(1):226. https:\/\/www.mdpi.com\/1453746.","DOI":"10.3390\/diagnostics12010226"},{"issue":"3","key":"16291_CR7","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1111\/jog.15540","volume":"49","author":"HJ Luo","year":"2023","unstructured":"Luo HJ, Hu ZD, Cui M, Zhang XF, Tian WY, Ma CQ, Ren YN, Dong ZL. Diagnostic performance of CA125, HE4, ROMA, and CPH-I in identifying primary ovarian cancer. J Obstet Gynaecol Res. 2023;49(3):998\u20131006.","journal-title":"J Obstet Gynaecol Res"},{"issue":"1","key":"16291_CR8","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1757-2215-5-20","volume":"5","author":"G Kalapotharakos","year":"2012","unstructured":"Kalapotharakos G, Asciutto C, Henic E, Cassl\u00e9n B, Borgfeldt C. High preoperative blood levels of HE4 predicts poor prognosis in patients with ovarian cancer. J Ovarian Res. 2012;5(1):20.","journal-title":"J Ovarian Res"},{"issue":"7","key":"16291_CR9","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1515\/cclm-2017-1176","volume":"56","author":"C Yuan","year":"2018","unstructured":"Yuan C, Li R, Yan S, Kong B. Prognostic value of HE4 in patients with ovarian cancer. Clin Chem Lab Med. 2018;56(7):1026\u201334.","journal-title":"Clin Chem Lab Med"},{"issue":"2","key":"16291_CR10","doi-asserted-by":"publisher","first-page":"188503","DOI":"10.1016\/j.bbcan.2021.188503","volume":"1875","author":"M Zhang","year":"2021","unstructured":"Zhang M, Cheng S, Jin Y, Zhao Y, Wang Y. Roles of CA125 in diagnosis, prediction, and oncogenesis of ovarian cancer. Biochim Biophys Acta Rev Cancer. 2021;1875(2):188503.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"7","key":"16291_CR11","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1038\/bjc.2011.328","volume":"105","author":"RY Zang","year":"2011","unstructured":"Zang RY, Harter P, Chi DS, Sehouli J, Jiang R, Trop\u00e9 CG, Ayhan A, Cormio G, Xing Y, Wollschlaeger KM, et al. Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort. Br J Cancer. 2011;105(7):890\u20136.","journal-title":"Br J Cancer"},{"issue":"3","key":"16291_CR12","doi-asserted-by":"publisher","first-page":"e0194270","DOI":"10.1371\/journal.pone.0194270","volume":"13","author":"A Chudecka-G\u0142az","year":"2018","unstructured":"Chudecka-G\u0142az A, Cymbaluk-P\u0142oska A, W\u0119\u017cowska M, Menkiszak J. Could HE4 level measurements during first-line chemotherapy predict response to treatment among ovarian cancer patients? PLoS ONE. 2018;13(3):e0194270.","journal-title":"PLoS ONE"},{"issue":"4","key":"16291_CR13","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1272\/jnms.84.170","volume":"84","author":"T Matsuhashi","year":"2017","unstructured":"Matsuhashi T, Takeshita T, Yamamoto A, Kawase R, Yamada T, Kurose K, Doi D, Konnai K, Onose R, Kato H. Serum CA 125 level after neoadjuvant chemotherapy is predictive of prognosis and debulking surgery outcomes in advanced epithelial ovarian cancer. J Nippon Med Sch. 2017;84(4):170\u20136.","journal-title":"J Nippon Med Sch"},{"issue":"1","key":"16291_CR14","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s13048-020-00681-0","volume":"13","author":"S Piatek","year":"2020","unstructured":"Piatek S, Panek G, Lewandowski Z, Bidzinski M, Piatek D, Kosinski P, Wielgos M. Rising serum CA-125 levels within the normal range is strongly associated recurrence risk and survival of ovarian cancer. J Ovarian Res. 2020;13(1):102.","journal-title":"J Ovarian Res"},{"issue":"4","key":"16291_CR15","doi-asserted-by":"publisher","first-page":"559","DOI":"10.3233\/CBM-210156","volume":"32","author":"YC Liao","year":"2021","unstructured":"Liao YC, Ou YC, Wu CH, Fu HC, Tsai CC, Lin H. CA125 normalization within 60 days as an independent prognostic factor for patients with advanced epithelial ovarian cancer. Cancer Biomark. 2021;32(4):559\u201367.","journal-title":"Cancer Biomark"},{"issue":"4","key":"16291_CR16","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.21037\/gs-20-544","volume":"9","author":"P Giampaolino","year":"2020","unstructured":"Giampaolino P, Foreste V, Della Corte L, Di Filippo C, Iorio G, Bifulco G. Role of biomarkers for early detection of ovarian cancer recurrence. Gland Surg. 2020;9(4):1102\u201311.","journal-title":"Gland Surg"},{"key":"16291_CR17","doi-asserted-by":"crossref","unstructured":"Charkhchi P, Cybulski C, Gronwald J, Wong FO, Narod SA, Akbari MR. CA125 and ovarian cancer: a comprehensive review. Cancers (Basel). 2020;12(12):3730. https:\/\/www.mdpi.com\/921412.","DOI":"10.3390\/cancers12123730"},{"issue":"5","key":"16291_CR18","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1038\/sj.bjc.6606092","volume":"104","author":"T Van Gorp","year":"2011","unstructured":"Van Gorp T, Cadron I, Despierre E, Daemen A, Leunen K, Amant F, Timmerman D, De Moor B, Vergote I. HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the risk of ovarian malignancy algorithm. Br J Cancer. 2011;104(5):863\u201370.","journal-title":"Br J Cancer"},{"issue":"24","key":"16291_CR19","doi-asserted-by":"publisher","first-page":"7422","DOI":"10.7150\/jca.62440","volume":"12","author":"L Gao","year":"2021","unstructured":"Gao L, Nie X, Gou R, Qi Y, Liu J, Lin B. Interaction of CD147 and human epididymis protein 4 promotes invasion and metastasis of ovarian cancer. J Cancer. 2021;12(24):7422\u201335.","journal-title":"J Cancer"},{"issue":"7","key":"16291_CR20","first-page":"4017","volume":"12","author":"L Zhu","year":"2020","unstructured":"Zhu L, Gou R, Guo Q, Wang J, Liu Q, Lin B. High expression and potential synergy of human epididymis protein 4 and Annexin A8 promote progression and predict poor prognosis in epithelial ovarian cancer. Am J Transl Res. 2020;12(7):4017\u201330.","journal-title":"Am J Transl Res"},{"issue":"1","key":"16291_CR21","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13048-020-00759-9","volume":"14","author":"Y Rong","year":"2021","unstructured":"Rong Y, Li L. Early clearance of serum HE4 and CA125 in predicting platinum sensitivity and prognosis in epithelial ovarian cancer. J Ovarian Res. 2021;14(1):2.","journal-title":"J Ovarian Res"},{"key":"16291_CR22","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.ygyno.2023.12.021","volume":"181","author":"A AlSomairi","year":"2024","unstructured":"AlSomairi A, Himayda S, Altelmesani A, Lee YJ, Lee JY. Prognostic value of HE4 in advanced-stage, high-grade serous ovarian cancer: Analysis of HE4 kinetics during NACT, predicting surgical outcome and recurrence in comparison to CA125. Gynecol Oncol. 2024;181:155\u201361.","journal-title":"Gynecol Oncol"},{"issue":"4","key":"16291_CR23","first-page":"211","volume":"20","author":"\u0141 Janas","year":"2021","unstructured":"Janas \u0141. Current clinical application of serum biomarkers to detect and monitor ovarian cancer - update. Prz Menopauzalny. 2021;20(4):211\u20136.","journal-title":"Prz Menopauzalny"},{"issue":"1","key":"16291_CR24","doi-asserted-by":"publisher","first-page":"e22624","DOI":"10.1002\/jcla.22624","volume":"33","author":"B Kim","year":"2019","unstructured":"Kim B, Park Y, Kim B, Ahn HJ, Lee KA, Chung JE, Han SW. Diagnostic performance of CA 125, HE4, and risk of ovarian malignancy algorithm for ovarian cancer. J Clin Lab Anal. 2019;33(1):e22624.","journal-title":"J Clin Lab Anal"},{"issue":"2","key":"16291_CR25","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.ygyno.2012.11.023","volume":"128","author":"EI Braicu","year":"2013","unstructured":"Braicu EI, Fotopoulou C, Van Gorp T, Richter R, Chekerov R, Hall C, Butz H, Castillo-Tong DC, Mahner S, Zeillinger R, et al. Preoperative HE4 expression in plasma predicts surgical outcome in primary ovarian cancer patients: results from the OVCAD study. Gynecol Oncol. 2013;128(2):245\u201351.","journal-title":"Gynecol Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16291-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16291-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16291-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T04:02:35Z","timestamp":1786334555000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16291-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16291"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16291-w","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]},"assertion":[{"value":"29 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Ethics Committee of Tengzhou Central People\u2019s Hospital (Approval No. 2023-15). The study was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all participants or their legal guardians prior to enrollment.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"957"}}